Research programme: HIV replication inhibitors - Pfizer

Drug Profile

Research programme: HIV replication inhibitors - Pfizer

Alternative Names: PF 821386; PF-821385; UK-201844

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Piperazines; Pyridines; Small molecules
  • Mechanism of Action HIV replication inhibitors; Viral envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported HIV infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA
  • 17 Apr 2008 Antimicrobial and pharmacokinetics data from a preclinical trial in HIV infections presented at the 21st International Conference on Antiviral Research (ICAR-2008)
  • 23 Feb 2006 Preclinical trials in HIV infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top